title: Differential startle reactivity following central CCK-8S and systemic Boc CCK-4 administration in mice: antecedent stressor history and testing condition.
abstract: The influence of intraventricular cholecystokinin-8S (CCK-8S) and systemic N-t-Boc-Trp-Met-Asp-Phe-amide (Boc CCK-4) was evaluated in the acoustic and fear-potentiated startle paradigms in CD-1 mice. In the light + tone startle condition. CCK-8S increased startle 168 hr after administration, compared with saline. In the tone startle condition, CCK-8S decreased startle immediately and 24 hr after administration, compared with saline. Among nonshocked mice, CCK-8S increased startle at 48 and 168 hr, compared with saline. In the light + tone condition, 5 microg Boc-CCK-4 did not influence startle, whereas 15 microg Boc CCK-4 decreased startle immediately, 24 hr, and 48 hr following administration. Results demonstrate that antecedent environmental experiences interact with subsequent pharmacological challenges in provoking the temporal expression of alterations in startle magnitude.
authors.affiliation: Institute of Neuroscience, Carleton University, Ottawa, Ontario, Canada. alohebb@dal.ca
authors.forename: Andrea L O
authors.initials: AL
authors.lastname: Hebb
authors.forename: Robert M
authors.initials: RM
authors.lastname: Zacharko
authors.forename: Josh P
authors.initials: JP
authors.lastname: Bowie
authors.forename: Guy
authors.initials: G
authors.lastname: Drolet
mesh_terms: D000161:Acoustic Stimulation; D000818:Animals; D005239:Fear; D007262:Infusions, Intravenous; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D018697:Nootropic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D013216:Reflex, Startle / Q000187:drug effects*; D012844:Sincalide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D013758:Tetragastrin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*
chemical_list: C090019:8-sulfocholecystokinin octapeptide; D018697:Nootropic Agents; D013758:Tetragastrin; C063051:butyloxycarbonyl-tryptophyl-methionyl-aspartyl-phenylalaninamide; D012844:Sincalide